SKTG 最新10-Q变化
将 SKTG 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-20 与上一份 10-Q · 2025-11-19
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +145 | −162 | ~13 | 24 |
| 市场风险(第3项) | 文字有新增/删除 | +22 | −50 | ~18 | 20 |
| 控制与程序 | 文字有新增/删除 | +22 | −50 | ~18 | 20 |
| 法律诉讼 | 文字有新增/删除 | +22 | −50 | ~18 | 20 |
| 风险因素 | 文字有新增/删除 | +22 | −50 | ~18 | 20 |
| 其他信息 | 文字有新增/删除 | +22 | −50 | ~17 | 20 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Management Discussion & Analysis of Financial Condition & Results of Operations
SkyTech Orion Global Corp. (the “Company”) is a U.S.-based corporation, with subsidiaries in Israel, focused on building end-to-end drone solutions from innovative modular drone platforms to large-scale production.
The Company is building a multi-layered industrial and modular infrastructure focused on the drone and defense sectors, combining proprietary in-house development, OEM capabilities, strategic partnerships, and targeted mergers and acquisitions (M&A). This structure is designed to address the growing…
The core of the Company’s technology is a proprietary modular architectural approach based on the separation between intelligent core systems and the drone’s airframe, power systems, sensors, communications, and payload components.
This approach enables the use of a standardized core unit, the Smart Core Unit™, which integrates with a wide range of airframes, propulsion systems, sensors, and payloads, thereby enabling high flexibility, shortened development cycles, and efficient scalability across multiple platforms and use ca…
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Citrine Global Corp. (DBA SkyTech Orion Global Corp.) reports that the Company has formally changed its corporate name in the State of Delaware to SkyTech Orion Global Corp. and is currently completing the corresponding name-change procedures with FINRA.
As previously described, during 2024–2025 we emerged from a challenging period for the Company, for Israel, and for the global environment in which we operate, following the events of October 7, 2023 and the resulting war, which significantly affected the Israeli economy and the activities of our su…
Based on this assessment, we made a strategic decision not merely to continue our operations, but to transform the Company’s vision, structure, and activities to align with the developing global defense, unmanned systems, and advanced drone markets. This process resulted in the Company’s transition …
We developed the SkyTech Replicator™, a modular, multi-mission drone platform based on a single Core Unit and our proprietary Click & Fly™ mechanism, enabling rapid mission reconfiguration and real-time adaptation for defense and dual-use applications. In parallel, we filed multiple patent applicati…
To support industrial scalability, we created the Replication Manufacturing Method, enabling rapid replication of production lines using advanced manufacturing and 3D-printing technologies, in collaboration with Stratasys, a global leader in additive manufacturing. Furthermore, our Israeli subsidiar…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-20
Basic weighted average number of shares of common stock outstanding 1,247,855,009 1,044,074,409
Common stock Additional paid-in Stock to be Accumulated Accumulated
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2026:
Common stock Additional paid-in Stock to be Accumulated Accumulated
Accounts payable and accrued expenses – related parties 189 176
相对上期删除的文字 · 来源:10-Q · 2025-11-19
Fair value measurement of the IBOT options and impairment of Nanomedic investments (432) (747) - -
The accompanying notes are an integral part of the condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
(U.S. dollars in thousands, except share and per share data)
Common stock Additional paid-in Stock to be Accumulated Accumulated other comprehensive Total stockholders’
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议